

Sun Pharma's growth pill coated with innovation

Specialty portfolio powers Q2; Ilumya, Leqselvi, Unloxyct to anchor next phase


RAM PRASAD SAHU
Mumbai, 6 November

India's largest pharmaceutical company, Sun Pharmaceutical Industries, reported a strong revenue performance for the July-September quarter (Q3) of 2025-26 (FY26), driven by key segments and geographies. Better than expected margins and lower research and development spending lifted operational performance. With a robust product pipeline and sustained growth momentum across markets, several brokerages have upgraded the stock, while others have maintained their 'buy' ratings. Revenue for the quarter rose 8.6 per cent year-on-year (Y-o-Y), ahead of estimates, led by India (up 11 per cent) and the Rest of the World market (up 23 per cent). The US generics business continues to weigh on overall performance, but this was offset by 16 per cent growth in the global innovative medicines (specialty) portfolio.

Apart from pricing pressure on the generic version of blood cancer drug Revlimid, the company highlighted price erosion in other base business products as well. It remains uncertain when pricing conditions will stabilise. The standout performance came from the global innovative portfolio, which grew 16.4 per cent Y-o-Y and 7 per cent sequentially. In the US, innovative medicine sales surpassed generics for the first time in Q2 FY26. Elara Securities said that the launch of flagship product Ilumya—used to treat plaque psoriasis—in newer markets is helping offset slowing growth in the US, where the product is maturing. Other contributors to the innovative portfolio included Cequa (for dry eyes) and the acne formulation Winlevi.



Stock health check



expects it to contribute \$110-125 million over FY26F (FY27). In addition, the planned launch of Unloxyct in the second half of FY26F (potential revenue: \$50-70 million over FY26F-FY27) and dossier filings in the European Union are expected to further strengthen the franchise. The long-awaited launch of Ilumya for psoriatic arthritis by end-FY26 should further bolster overall Ilumya sales. Together, these products are expected to offset the Revlimid cliff and generate about \$200 million in incremental US revenue. Given the superior margin profile of innovative medicines, analyst Yogesh Soni of IncRed expects margin expansion to begin from FY27. The brokerage has upgraded the stock to 'accumulate' and raised its target price to ₹2,000 from ₹1,000. Motilal Oswal, however, has trimmed its FY26-28 earnings estimates by 3-6 per cent, factoring in higher marketing expenses for global innovative medicines and a higher tax rate. It has nevertheless maintained a 'buy' rating, with a target price of ₹1,960. Analysts led by Tushar Mudhane said Sun continues to strengthen its branded portfolio across both developed and emerging markets. Product launches and deeper market penetration are expected to sustain the company's strong growth trajectory, keeping it ahead of largecap peers in the Indian pharma space.

launched the hair loss drug Leqselvi and plans to introduce the skin cancer therapy Unloxyct soon. Analysts at Elara Securities, led by Bino Pathiparampl, believe these acquired products can help sustain growth in Sun's innovative segment, with each expected to generate over \$200 million in sales within three to four years. The brokerage has raised its FY26 through to 2027-28 (FY28) core earnings per share estimates by 4.5 per cent and increased its target price from ₹1,871 to ₹1,968 per share. IncRed Equities also expects the innovative portfolio—which has delivered 23 per cent annual growth over the past five years—to maintain momentum in the medium term, supported by a strong launch pipeline. Sun introduced Leqselvi in the US during Q2 of 2024-25 and

YOUR MONEY

ALGO TRADING

Trade with multiple stop-losses, risk limits

HIMALI PATEL

Securities & Exchange Board of India (Sebi) Chairman Tuhin Kanta Pandey said recently that the rise of algorithmic trading brings efficiency but also demands robust risk controls and real-time monitoring. Here is a look at the key risks retail investors face in algo trading and how they can manage them.

Myriad risks

Liquidity is a major concern. Many stocks and options in India are illiquid, with shallow market depth and wide bid-ask spreads. Orders may not get filled or may execute at worse than expected prices, which is called slippage. "Slippage becomes a major issue if liquidity is not factored in," says Rajesh Ganesh, founder & chief executive officer (CEO), Tripleint Trading Systems. Retail investors may also rely excessively on back-tested results or use poorly coded strategies. "Lack of real-time monitoring can cause significant losses if something goes wrong," says Vikas Singhania, chief executive officer (CEO), TradeSmart. Black-swan events can worsen losses. "Inad-

Key dos and don'ts

- Do paper trading, or live runs with small amounts of capital
- Understand algo's logic, risk controls, and fallback mechanisms
- Scale based on profits, not to recover losses
- Don't jump between systems after a small loss or drawdown
- Don't ignore updates or assume the algo will handle all market conditions
- Control emotions, track performance daily and keep refining the strategy

equate stop-loss settings can trigger rapid drawdowns. Says Harsh Virra, chief financial planner & founder, FinPro Wealth.

Don't rely blindly on back-tested results

Back-tests often fail to reflect real-world trading. Strategies that excel in back tests often fail in live trading. "A reliable back test must include realistic costs, slippage, and drawdowns," says Virra. Short testing periods, cherry-

picked timeframes and mismatched conditions are red flags. "An algo performing well in a bullish phase may wipe out capital in a flat or negative market," says Ramakrishnan Selvaraj, cofounder, coinburst bot. Investors should also examine peak-to-trough draw-downs and how long recovery took. One-off large profits or losses skewing results are red flags. Unrealistic outcomes are another warning sign. "A 100 per cent win rate or an extremely high Sharpe ratio is a red flag," says Singhania.

Watch out for operational risks

Tech failures, connectivity issues, API disruptions, broker downtime, exchange outages and order rejections can all disrupt execution. They can lead to missed entries or exits. Reliability of infrastructure also matters. "Retail investors should avoid Excel-based trading," says Selvaraj. Instead, use a stable and tested platform, ideally cloud-based or broker-hosted. "Hedged strategies help cap maximum risk even if the algo cannot execute due to technical issues," says Ganesh.

Manage risks

Algo trading should be segregated in a separate account with only risk capital deployed. Selvaraj recommends three layers of stop-losses—position-level, portfolio-level and maximum stop-loss. Traders should also implement per-trade, daily, weekly and monthly risk limits. "If any limit is breached, reduce position size or switch to paper trading," says Ganesh. Traders should not deploy all their capital in algo trading. They should maintain reserves for margin calls. Position sizing must

be disciplined. Avoid allocating more than a fixed percentage of capital to a single trade. Diversification also helps. "Use diversified strategies and test them in paper trading before going live," says Virra.

Control costs

Algo platforms focus on building profitable strategies, but it is the investor's job to account for real-world costs. "Costs can be so large that even an algo with a positive edge may lose money," says Ganesh. "Too many trades—especially in options and futures—can lead to high brokerage, commissions and taxes, turning a profitable algo negative in the investor's account," says Selvaraj. "Slippage, impact cost (which increases for large orders in illiquid stocks), subscription and infrastructure costs (VPS, API, platform fees) must be factored in," says Singhania.

According to Virra, such costs can reduce real profits by 20-40 per cent compared to back tests, so simulations should be carried out before going live.

Robust monitoring required

Monitoring should ideally be real-time or at least every 15-30 minutes. "Set up auto-alerts via short message service (SMS), email, or app notifications for drawdown breaches, margin shortfalls, or order failures," says Singhania. Traders should review an end-of-day summary of profits and losses, open positions and system health. They should also maintain a manual override or kill switch. Retail algos can also be supervised via automated dashboards.

The writer is a Mumbai-based independent writer

Porting health insurance? Here's what you should watch out for

Health insurance portability allows you to move from one insurer to another without losing accrued benefits, such as waiting period credits. But experts caution that poor timing, incomplete paperwork, or non-disclosure of health details can derail the process, leaving you exposed to fresh waiting periods or even policy lapses.

Don't wait till the last moment "One of the mistakes customers make while porting is to wait until their policy is about to expire," says Siddharth Singh, head of health insurance at Policybazaar. If there's any break in the policy, for example, if the grace period lapses before the new insurer issues the policy, customers may lose their continuity benefits.

When porting makes sense ● Porting is ideal when your current policy no longer fits your needs, and you want to retain waiting period benefits. ● It is particularly useful when upgrading from ₹5 lakh to ₹10 lakh coverage or when moving to an insurer with stronger hospital tie-ups and smoother claims service. ● It also makes sense if your insurer

has hiked premiums significantly "without enhancing benefits" or if the new insurer offers better claim settlement ratios, customer service.

Avoiding rejections

Rejections occur due to incomplete disclosures/high perceived health risk. Red flags include advanced age, multiple hospitalisations, or undisclosed pre-existing conditions.

Read full report here: mybs.in/2erZlR

COMPILED BY AMIT KUMAR

In fast or fragile markets, insight brings perspective.

Decode market moves with sharp, fast, expert analysis every day with Stocks in the News Business Standard.

To book your copy, SMS reaches to 97878 or email order@bsnl.in

Business Standard
Insight Out

THE ASKA COOPERATIVE SUGAR INDUSTRIES LTD.
P.O. Nuagam (Aska) - 761111, Ganjam District, Odisha
E-mail: askasugar@yahoo.co.in
GSTIN: 21AAAN5989L120

TENDER CALL NOTICE

No. PUR/1734 Date: 06.11.2025

The Aska Cooperative Sugar Industries Ltd. at Nuagam, Aska in Ganjam District of Odisha state invites sealed quotations from Manufacturer/Dealers/Supplier having GSTIN for supply of VFD, ABB AC centrifuge pump 200KW and 125KVA DG (100KW) Mame Cummins. Parties are requested to give their offer with detail terms & conditions. Please visit our website www.askasugar.com for details of the Tender Call Notice.

Managing Director

TATA POWER DELHI DISTRIBUTION LIMITED
A Tata Power and Delhi Government Joint Venture
Regd. Office: NDRP House, Hudson Lines, Kingsway Camp, Delhi-110 008
CIN No. U40109DL200PLC111525 Website: tatapower-dcl.com

NOTICE INVITING TENDERS Nov 07, 2025

TATA Power-DCL invites tenders as per following details:

Tender Enquiry No.	Work Description	Estimated Cost/EMD (Rs.)	Availability of Bid Document	Last Date & Time of Bid Submission Date and time of Opening of bids
TPDDEL/ENG/200001181/25-26	2 Yr RC for Supply of Precast IT Plinths Slab Type as per TPO	1.52 Crn/ 1.89 Lacs	07.11.2025	27.11.2025, 1300 Hrs/ 27.11.2025, 1330 Hrs
TPDDEL/ENG/2000182/25-26	RC for supply of 33 KV Cables with Returnable drums at TPDCL Site/Store	4.92 Crn/ 9.39 Lacs	07.11.2025	28.11.2025, 1500 Hrs/ 28.11.2025, 1530 Hrs

Complete tender and corrigendum document is available on our website www.tatapower-dcl.com—Vendor Zone —Tender/ Corrigendum Documents

DIAGEO
India

UNITED SPIRITS LIMITED
Corporate Identity Number: L01551KA1969PLC024991
Regd. Office: UB Tower #24, Vitali Malvi Road, Bengaluru - 560 001, Karnataka, India.
Tel: +91 80 2221 0705 | Fax: +91 80 2225 5253
Email: investor.india@diageo.com | Website: www.diageoindia.com

NOTICE OF LOSS OF SHARE CERTIFICATES

Notice is hereby given that the Company has received requests from the following shareholder(s) for issuance of the Certificate of Confirmation in lieu of Original Share Certificate(s) reported to have been lost/misplaced. The share certificate(s) mentioned hereunder are therefore deemed to be cancelled and no transactions thereon would be recognized by the Company.

Sl. No.	Folio No.	Name of the Shareholder	No. of Shares	Certificate Number	Distinctive Nos
01	MS070927	ROHINI BHALCHANDRA KAMBLE	500	2723	721278611 - 721279310

The public are hereby advised against dealing in any way with the above share certificates. Any person(s) who has/ have any claim(s) in respect of the said share certificates are requested to lodge such claim(s) along with all documentary evidences with the Company at its Registered Office within 7 (seven) days of publication of this notice, after which no claim(s) will be entertained, and the Company shall proceed to issue a Certificate of Confirmation in accordance with applicable SEBI regulations.

For UNITED SPIRITS LIMITED
Pragya Kaul
Company Secretary and Compliance Officer

Place : Bengaluru
Dated : November 06, 2025

JAGRAN PRAKASHAN LIMITED										
CIN:L22219UP1975PLC004147										
Registered Office: Jagran Building, 2, Sarvodaya Nagar, Kanpur-208005										
Tel: +91 512 2216611 Website: www.jpcorp.in , E-mail: investor@jpcorp.in										
Extract of Unaudited Consolidated Financial Results for the Quarter and Half-year ended September 30, 2025										
(Rs in Lakhs, except per share data)										
Particulars	Quarter Ended 30.09.2025	Quarter Ended 30.06.2025	Quarter Ended 30.09.2024	Half-year Ended 30.09.2025	Half-year Ended 30.09.2024	Quarter Ended 30.09.2024	Half-year Ended 30.09.2024	Half-year Ended 30.09.2024	Year Ended 31.03.2025	Year Ended 31.03.2024
Total Income from operations (net)	46,736.07	46,005.23	44,650.85	92,741.30	89,062.70	1,86,813.14				
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	7,103.28	9,023.08	6,232.99	16,126.36	11,973.75	13,632.50				
Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items and share of net profit / (loss) of Associates)	7,113.80	9,036.61	6,234.39	16,150.41	11,980.86	13,661.31				
Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax))	5,758.42	6,676.07	4,157.74	12,434.49	8,261.19	9,076.04				
Paid up Equity Share Capital (Face value Rs. 2/- per share)	4,353.09	4,353.09	4,353.09	4,353.09	4,353.09	4,353.09				
Earnings Per Share (Face value of Rs. 2/- each) (not annualized)										
- Basic	269	309	197	578	386	602				
- Diluted	269	309	197	578	386	602				

- Notes:**
- The above is an extract of the detailed format of quarter / half-year ended Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of quarter and half-year ended Financial Results, the pertinent disclosures have been made and are available on the websites of the Stock Exchanges i.e. www.nseindia.com and www.bseindia.com and also available on the Company's website at www.jpcorp.in.
 - The above results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 6, 2025 and has been subject to limited review of the statutory auditors of the Company.
 - Summary of Key Unaudited Standalone Financial Results is as follows:

Particulars	Quarter Ended 30.09.2025	Quarter Ended 30.06.2025	Quarter Ended 30.09.2024	Half-year Ended 30.09.2025	Half-year Ended 30.09.2024	Year Ended 31.03.2025
Total revenue from operations	41,377.14	39,613.14	37,575.75	81,190.28	74,620.37	1,58,963.96
Profit before Tax	7,778.71	9,473.10	6,009.36	17,251.81	12,865.87	28,763.71
Profit after Tax	6,172.75	7,134.53	4,736.53	13,307.28	9,134.35	21,111.61
Total Comprehensive Income	6,172.75	7,134.53	4,736.53	13,307.28	9,134.35	20,837.24

Scan QR Code for complete financial results



For Jagran Prakashan Limited
Sol.-
Mahendra Mohan Gupta
(Non-Executive Chairman)

Date: 06-11-2025
Place: Kanpur

BAJAJ HOUSING FINANCE LIMITED

CIN: L65910PN2008PLC132228 | Registered Office: Bajaj Auto Limited Complex, Mumbai-Pune Road, Akurdi, Pune - 411 035
Corporate Office: 5th Floor, B2 Building, Cerebrum IT Park, Kumar City, Kalyani Nagar, Pune 411014.
Tel: 020-71870601 | E-mail: bhfinvestor.service@bajajhousing.co.in | Website: www.bajajhousingfinance.in

Extract of unaudited financial results for the Quarter and Half year ended 30 September 2025

Sr. No.	Particulars	Quarter Ended 30.09.2025 (Unaudited)	Half Year Ended 30.09.2025 (Unaudited)	Quarter Ended 30.09.2024 (Unaudited)
1	Revenue from operations	2,754.85	5,370.56	2,410.15
2	Profit before tax	832.66	1,589.60	707.59
3	Profit after tax	642.96	1,226.26	545.60
4	Total comprehensive income (Comprising profit for the period and other comprehensive income after tax)	627.38	1,215.23	550.82
5	Paid-up equity share capital	8,328.61	8,328.61	8,328.15
6	Other equity as shown in Balance Sheet of the previous year			11,618.65
7	Earnings per share (Face value of ₹10/- each) (not annualised)			
a. Basic (₹)		0.77	1.47	0.69
b. Diluted (₹)		0.77	1.47	0.69

Notes:

The above is an extract of the unaudited financial results for the quarter and half year ended 30 September 2025 which have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 6 November 2025 and subjected to limited review by joint statutory auditors and filed with the stock exchange under Regulation 33 and 52 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. These financial results have been prepared in accordance with Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time and other recognised accounting practices generally accepted in India along with the circulars, guidelines and directions issued by the Reserve Bank of India (RBI) and the National Housing Bank (NHB) from time to time. The full format of the aforesaid financial results is available on the website of the Company, BSE India and National Stock Exchange of India Limited i.e. www.bajajhousingfinance.in and www.bseindia.com and www.nseindia.com respectively. The same can be accessed by scanning the QR code provided below.

By order of the Board of Directors
For Bajaj Housing Finance Limited

Atul Jain
Managing Director
DIN: 09567172

Pune
6 November 2025

